Cargando…
Biological therapy for ulcerative colitis
Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD) worldwide. Better understanding of the pathogenesis of UC has led to the development of novel therapeutic agents that target specific mediators of the inflammatory cascade. A number of biological agents have been approved by...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423460/ https://www.ncbi.nlm.nih.gov/pubmed/25344680 http://dx.doi.org/10.1093/gastro/gou070 |
_version_ | 1782370215158349824 |
---|---|
author | Arora, Zubin Shen, Bo |
author_facet | Arora, Zubin Shen, Bo |
author_sort | Arora, Zubin |
collection | PubMed |
description | Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD) worldwide. Better understanding of the pathogenesis of UC has led to the development of novel therapeutic agents that target specific mediators of the inflammatory cascade. A number of biological agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of UC and several more are currently in various phases of drug development. The commonly used agents include TNFα antagonists (e.g. infliximab, adalimumab, and golimumab) and anti-integrin agents (vedolizumab). These biological agents have profoundly influenced the management of UC patients, especially those with refractory disease. This paper reviews the currently available knowledge and evidence for the use of various biological agents in the treatment of UC. |
format | Online Article Text |
id | pubmed-4423460 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44234602015-05-13 Biological therapy for ulcerative colitis Arora, Zubin Shen, Bo Gastroenterol Rep (Oxf) Reviews Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD) worldwide. Better understanding of the pathogenesis of UC has led to the development of novel therapeutic agents that target specific mediators of the inflammatory cascade. A number of biological agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of UC and several more are currently in various phases of drug development. The commonly used agents include TNFα antagonists (e.g. infliximab, adalimumab, and golimumab) and anti-integrin agents (vedolizumab). These biological agents have profoundly influenced the management of UC patients, especially those with refractory disease. This paper reviews the currently available knowledge and evidence for the use of various biological agents in the treatment of UC. Oxford University Press 2015-05 2014-10-24 /pmc/articles/PMC4423460/ /pubmed/25344680 http://dx.doi.org/10.1093/gastro/gou070 Text en © The Author(s) 2014. Published by Oxford University Press and the Digestive Science Publishing Co. Limited. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Arora, Zubin Shen, Bo Biological therapy for ulcerative colitis |
title | Biological therapy for ulcerative colitis |
title_full | Biological therapy for ulcerative colitis |
title_fullStr | Biological therapy for ulcerative colitis |
title_full_unstemmed | Biological therapy for ulcerative colitis |
title_short | Biological therapy for ulcerative colitis |
title_sort | biological therapy for ulcerative colitis |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423460/ https://www.ncbi.nlm.nih.gov/pubmed/25344680 http://dx.doi.org/10.1093/gastro/gou070 |
work_keys_str_mv | AT arorazubin biologicaltherapyforulcerativecolitis AT shenbo biologicaltherapyforulcerativecolitis |